ABSTRACT
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by deficiency of alpha-L-iduronidase (IDUA). Limitations such as the need for weekly injections, high morbidity and mortality, and high cost of current treatments show that new approaches to treat this disease are required. In this study, we aimed to correct fibroblasts from a patient with MPS I using non-viral gene therapy. Using a plasmid encoding the human IDUA cDNA, we achieved stable high IDUA levels in transfected fibroblasts up to 6 months of treatment. These results serve as proof of concept that a non-viral approach can correct the enzyme deficiency in cells of patients with lysosomal storage disorders, which can be used as a research tool for a series of disease aspects. Future studies should focus on showing if this approach can be useful in small animals and clinical trials (AU)
Subject(s)
Humans , Fibroblasts/enzymology , Gene Transfer Techniques , Genetic Vectors , Iduronidase/metabolism , Mucopolysaccharidosis I/therapy , DNA, Complementary , Genetic Therapy/methods , Iduronidase/genetics , Mucopolysaccharidosis I/genetics , Plasmids/genetics , Transfection/methodsABSTRACT
Se reporta el caso de una niña de 18 meses de edad que presenta características fenotípicas de tipo "hurleroide, a la cual se le realizó la determinación de las enzimas relacionadas con el metabolismo de los mucopolisacáridos (MPS), así como la caracterización cinética de la enzima denominada alfa-L-iduronidasa, cuya deficiencia condujo al diagnóstico de dicha enfermedad